Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan 7;127(1):71-8.
doi: 10.1182/blood-2015-07-604538. Epub 2015 Dec 10.

Emerging therapeutic drugs for AML

Eytan M Stein  1 , Martin S Tallman  1
Affiliations
Review

Emerging therapeutic drugs for AML

Eytan M Stein et al. Blood. .

Abstract

Multiple new drugs are being developed to treat acute myeloid leukemia (AML), including novel formulations of traditional chemotherapy-antibody drug conjugates and agents that target specific mutant enzymes. Next-generation sequencing has allowed us to discover the genetic mutations that lead to the development and clinical progression of AML. Studies of clonal hierarchy suggest which mutations occur early and dominate. This has led to targeted therapy against mutant driver proteins as well as the development of drugs such as CPX-351 and SGN-CD33A whose mechanisms of action and efficacy may not be dependent on mutational complexity. In this brief review, we discuss drugs that may emerge as important for the treatment of AML in the next 10 years.

Trial registration: ClinicalTrials.gov NCT01696084.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CPX-351 vs 7+3 (7 days of cytarabine and 3 days of daunorubicin). OS for patients with secondary AML. Numbers in parentheses represent confidence intervals. Reprinted from Ravandi et al with permission.
Figure 2
Figure 2
OS in VALOR trial (intention to treat population). HR, hazard ratio.
Figure 3
Figure 3
OS estimates according to randomization and European Leukemia Net genetic group. (A) Favorable and intermediate I/II groups. Median OS times for patients who received LDC (n = 28) and LDC + volasertib (n = 22) were 7.8 and 9.8 months, respectively (HR, 0.54; 95% confidence interval [CI], 0.29-1.02). (B) Adverse group. Median OS times for patients who received LDC (n = 14) and LDC + volasertib (n = 14) were 3.3 and 5.9 months, respectively (HR, 0.63; 95% CI, 0.29-1.40). Database snapshot November 7, 2013.
See this image and copyright information in PMC

References

    1. Shlush LI, Zandi S, Mitchell A, et al. HALT Pan-Leukemia Gene Panel Consortium. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506(7488):328–333. - PMC - PubMed
    1. Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487–494. - PubMed
    1. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58(18):4173–4179. - PubMed
    1. Rowe JM. Important milestones in acute leukemia in 2013. Best Pract Res Clin Haematol. 2013;26(3):241–244. - PubMed
    1. Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol. 2006;135(2):165–173. - PubMed

MeSH terms

Substances

Associated data